Endothelial senescence orchestrates the tumor immune microenvironment and immunotherapy response in non-small cell lung cancer.
Abstract
The response of non-small cell lung cancer to immunotherapy is highly variable and shaped by a heterogeneous tumor microenvironment, yet the stromal drivers remain unclear. We identify senescent endothelial cells (ECs) as key regulators of immunotherapy efficacy. Multi-omics analyses across cancers reveal that ECs represent the most senescent stromal population, and clinically, their senescence correlates with improved immunotherapy response and prolonged survival. Functionally, these senescent ECs are enriched in cytokine signaling and immune activation pathways and enhance T-cell communication through FOSB expression. Cross-platform spatial transcriptomics and multiplex immunofluorescence reveal a distance-dependent association between senescent ECs, CD8+ T cell localization and function, and tertiary lymphoid structures, forming an immune-enriched niche mediated by the CXCL9-CXCR3 axis. Mechanistically, FOSB knockdown attenuates endothelial senescence and reduces CD8+ T cell recruitment and activation by decreasing CXCL9 secretion. These findings establish endothelial senescence as a critical modulator of antitumor immunity and promising target to enhance immunotherapy.